Thermo Fisher is a high-quality life sciences franchise trading at a discount to peers on price-to-sales (3.69x vs. peer median 4.61x) but at a premium on EV/EBITDA (18.5x vs. 16.6x). While fiscal 2025 revenue of $44.6B and EPS of $17.74 reflect a post‑COVID earnings recovery, a $40.9B debt load and declining gross margins temper enthusiasm. The stock trades below its 50‑ and 200‑day moving averages at an RSI of 39.7, but a surge in smart‑money fund ownership (score from 0.01 to 0.50 year‑over‑year) and Jefferies’ addition of TMO to its high‑conviction Buy list suggest institutional accumulation at these levels. Until the technical downtrend reverses and organic growth reaccelerates, a hold rating is appropriate.